Keqian Biology(SH:688526)2025-04-28 15:20Financial Performance - The company's revenue for Q1 2025 was CNY 245,188,828.52, representing a 19.65% increase compared to CNY 204,929,240.40 in the same period last year[3]. - Net profit attributable to shareholders was CNY 108,236,874.48, up 24.08% from CNY 87,228,395.78 year-over-year[3]. - Basic and diluted earnings per share increased by 27.78% to CNY 0.23 from CNY 0.18 in the previous year[4]. - Total operating revenue for Q1 2025 reached ¥245,188,828.52, an increase of 19.5% compared to ¥204,929,240.40 in Q1 2024[19]. - Net profit for Q1 2025 was ¥107,786,272.75, representing a 23.5% increase from ¥87,075,680.66 in Q1 2024[20]. - The company's total comprehensive income for Q1 2025 was ¥123,142,728.35, compared to ¥90,397,978.13 in Q1 2024, an increase of 36.3%[21]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,639,554,478.66, a 3.20% increase from CNY 4,495,821,916.06 at the end of the previous year[4]. - The company's current assets reached CNY 2,581,193,766.69, up from CNY 2,473,078,015.08, indicating an increase of about 4.4%[15]. - The company's total liabilities increased to ¥574,464,302.84 in Q1 2025, compared to ¥552,798,705.10 in Q1 2024, reflecting a growth of 3.1%[17]. - The total equity attributable to shareholders rose to ¥4,063,487,267.59 in Q1 2025, up from ¥3,940,969,701.00 in Q1 2024, marking an increase of 3.1%[17]. Cash Flow - The cash flow generated from operating activities was CNY 140,037,835.33, reflecting a 5.22% increase from CNY 133,086,579.74 in the same period last year[4]. - The cash inflow from operating activities for Q1 2025 showed a positive trend, indicating improved liquidity and operational efficiency[22]. - In Q1 2025, the cash inflow from operating activities was $315,702,694.25, an increase of 14.2% compared to $276,340,855.26 in Q1 2024[23]. - The net cash flow from operating activities for Q1 2025 was $140,037,835.33, up from $133,086,579.74 in Q1 2024, reflecting a growth of 5.4%[24]. - The cash outflow from financing activities in Q1 2025 was $1,105,814.69, compared to $177,480,673.80 in Q1 2024, showing a reduction of 99.4%[24]. Research and Development - Research and development expenses totaled CNY 21,330,798.19, accounting for 8.70% of revenue, down from 9.68% in the previous year[4]. - The company has committed to ongoing research and development to enhance its product offerings and market position[4]. - The company invested a total of 12,186,716.38 yuan in the research of the swine pseudorabies gene engineering live vaccine, achieving new veterinary drug registration[11]. - The company has established a cooperation research and development management system with Huazhong Agricultural University, ensuring competitive negotiation for future projects[10]. - The company is actively engaged in the research and development of various vaccines and diagnostic kits, with multiple products in different stages of clinical trials and registrations[12][13]. Shareholder Information - The largest shareholder, Wuhan Huazhong Agricultural University, holds 16.73% of the shares[9]. - The second-largest shareholder, Chen Huan Chun, holds 15.20% of the shares[9]. - The total number of ordinary shareholders at the end of the reporting period was 7,968[8]. - The company has not reported any changes in the participation of major shareholders in margin trading and securities lending[10].